A critical review of perfluorooctanoate and perfluorooctanesulfonate exposure and immunological health conditions in humans

• Published in: Critical reviews in toxicology Vol. 46; no. 4; pp. 279 - 331
• Main Authors: Chang, Ellen T., Adami, Hans-Olov, Boffetta, Paolo, Wedner, H. James, Mandel, Jack S.
• Format: Journal Article
• Language: English
• Published: England Taylor & Francis 20-04-2016
• Subjects: Alkanesulfonic Acids - poisoning; Alkanesulfonic Acids - toxicity; Animals; Asthma; Asthma - chemically induced; Asthma - epidemiology; autoimmune diseases; Caprylates - poisoning; Caprylates - toxicity; CAS No. 1763-23-1; CAS No. 335-67-1; Environmental Exposure - statistics & numerical data; epidemiology; Fluorocarbons - poisoning; Fluorocarbons - toxicity; Humans; hypersensitivity; immune system; Immune System - drug effects; Immune System Diseases - chemically induced; Immune System Diseases - epidemiology; immunization; immunological factors; Immunotoxins - poisoning; Immunotoxins - toxicity; infection; perfluoroalkyl substances; polyfluoroalkyl substances; Review; autoimmune diseases; perfluoroalkyl substances; epidemiology; infection; hypersensitivity; CAS No. 1763-23-1; immunization; immune system; immunological factors; polyfluoroalkyl substances; Asthma; CAS No. 335-67-1
• ISSN: 1040-8444; 1547-6898
• DOI: 10.3109/10408444.2015.1122573

Whether perfluorooctanoate (PFOA) and perfluorooctanesulfonate (PFOS), two widely used and biopersistent synthetic chemicals, are immunotoxic in humans is unclear. Accordingly, this article systematically and critically reviews the epidemiologic evidence on the association between exposure to PFOA and PFOS and various immune-related health conditions in humans. Twenty-four epidemiologic studies have reported associations of PFOA and/or PFOS with immune-related health conditions, including ten studies of immune biomarker levels or gene expression patterns, ten studies of atopic or allergic disorders, five studies of infectious diseases, four studies of vaccine responses, and five studies of chronic inflammatory or autoimmune conditions (with several studies evaluating multiple endpoints). Asthma, the most commonly studied condition, was evaluated in seven studies. With few, often methodologically limited studies of any particular health condition, generally inconsistent results, and an inability to exclude confounding, bias, or chance as an explanation for observed associations, the available epidemiologic evidence is insufficient to reach a conclusion about a causal relationship between exposure to PFOA and PFOS and any immune-related health condition in humans. When interpreting such studies, an immunodeficiency should not be presumed to exist when there is no evidence of a clinical abnormality. Large, prospective studies with repeated exposure assessment in independent populations are needed to confirm some suggestive associations with certain endpoints.